Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest Peyronie's disease Stories

2013-11-20 08:28:02

-Multiple Studies of XIAFLEX for the Potential Treatment of Peyronie's Disease to be Presented- CHESTERBROOK, Pa., Nov. 20, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully-integrated specialty biopharmaceutical company, today announced that data evaluating the use of XIAFLEX(®) (collagenase clostridium histolyticum or CCH) for the potential treatment of Peyronie's disease, will be presented at the upcoming 19(th) Annual Fall Scientific Meeting of the Sexual...

2013-11-18 08:29:33

- Results showed comparable improvement in joint contracture and range of motion to single injection in previous studies - LYNBROOK, N.Y., Nov. 18, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products marketed as XIAFLEX(® )(collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX(®) in the EU, today announced positive results from the open label, Phase IIIb MULTICORD...

2013-11-18 08:27:56

- Expects to submit supplemental Biologics License Application to the FDA in the first quarter of 2014 that supports potential labeling expansion for concurrent treatment of multiple palpable cords- CHESTERBROOK, Pa., Nov. 18, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced the results of the MULTICORD (Multiple Treatment Investigation of Collagenase Optimizing the Resolution of Dupuytren's)...

2013-11-12 08:35:32

LYNBROOK, N.Y., Nov. 12, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products marketed as XIAFLEX(® )(collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX(®) (the EU tradename for CCH) in the EU, today reported its financial results for the third quarter ended September 30, 2013 and provided a corporate update. "We are excited about the potential approval of CCH for Peyronie's...

2013-11-05 08:35:25

LYNBROOK, N.Y., Nov. 5, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX(®)( )in the EU, announced today that it will host a conference call and live audio webcast at 8:30 a.m. EST on Tuesday, November 12, 2013 to report its third quarter 2013 financial results and provide a corporate update....

2013-10-24 08:35:57

CHESTERBROOK, Pa., Oct. 24, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, will release results for the third quarter 2013 on Wednesday, November 6, 2013. The Company will also conduct a conference call that day at 10:00 a.m. ET to discuss results and highlights of the third quarter. The presentation slides to be used during the call will be available on the "For Investors" section of the Company's web site...

2013-10-23 12:28:57

- First patient dosed in Phase 2a randomized, double-blind multiple-dose study - LYNBROOK, N.Y., Oct. 23, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in the EU, today announced that its partner Auxilium Pharmaceuticals, Inc. (Auxilium) has dosed the first patient in its Phase 2a study of XIAFLEX ("collagenase clostridium...

2013-10-23 08:29:58

- Topline Results are Expected in the First Quarter of 2015 - CHESTERBROOK, Pa., Oct. 23, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully-integrated specialty biopharmaceutical company, today announced the first patient dosed in its Phase 2a study of collagenase clostridium histolyticum (or "CCH") for the treatment of edematous fibrosclerotic panniculopathy ("EFP"), commonly known as cellulite. As previously reported, Phase 1b open label dose-ranging...

2013-10-11 08:23:42

- STENDRA Broadens Auxilium's Presence in Men's Health Care With a Projected 2013 Launch into the Multi-Billion Dollar Erectile Dysfunction Market - CHESTERBROOK, Pa., Oct. 11, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, announced today the signing of an agreement with VIVUS, Inc. (Nasdaq: VVUS) providing Auxilium with the exclusive right to market VIVUS's product, STENDRA (avanafil), in the United States and Canada. The...

2013-10-07 16:25:31

- Clinical Papers Presented on Four-Year Data from CORDLESS Recurrence Study and Three-Year Safety Data - LYNBROOK, N.Y., Oct. 7, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in the EU, announced today that data from multiple trials evaluating the use of XIAFLEX ("collagenase clostridium histolyticum" or "CCH") in adult patients...